Cogent reaches FDA alignment on MS2D2 endpoint for SUMMIT trial; enrollment timeline reaffirmed

Cogent Biosciences, Inc.

FDA alignment on novel patient-reported outcome measure MS2D2 for Part 2 of SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM).
SUMMIT Part 2 enrollment on track to complete Q2 2025; top-line results expected by end of 2025.
APEX study (Advanced SM) enrollment to complete end of 2024; top-line results mid-2025.
PEAK study (GIST) enrollment expected to complete Q3 2024; top-line results by end of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.